Petersson M et al. |
Oxytocin stimulates proliferation of human osteoblast-like cells. |
2002 |
Peptides |
pmid:12126740
|
Cundy T et al. |
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. |
2002 |
Hum. Mol. Genet. |
pmid:12189164
|
Lee SK et al. |
1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. |
2002 |
J. Immunol. |
pmid:12193704
|
Chen XW et al. |
Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. |
2002 |
Biochem. Biophys. Res. Commun. |
pmid:12150965
|
Katagiri T and Takahashi N |
Regulatory mechanisms of osteoblast and osteoclast differentiation. |
2002 |
Oral Dis |
pmid:12108759
|
Granchi D et al. |
Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. |
2002 |
Biomaterials |
pmid:12013183
|
Li X et al. |
Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. |
2002 |
Prostaglandins Other Lipid Mediat. |
pmid:12013525
|
Bosshart H |
Expression of survival receptors in Hodgkin disease cell lines. |
2002 |
Blood |
pmid:12001908
|
Ono K et al. |
Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. |
2002 |
J. Bone Miner. Res. |
pmid:12009007
|
Fu Q et al. |
Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. |
2002 |
J. Biol. Chem. |
pmid:12364326
|
Rogers A et al. |
Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. |
2002 |
J. Clin. Endocrinol. Metab. |
pmid:12364420
|
Romas E et al. |
Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. |
2002 |
Am. J. Pathol. |
pmid:12368214
|
Standal T et al. |
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. |
2002 |
Blood |
pmid:12351414
|
Biskobing DM et al. |
Novel therapeutic options for osteoporosis. |
2002 |
Curr Opin Rheumatol |
pmid:12118183
|
Mizukami J et al. |
Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. |
2002 |
Mol. Cell. Biol. |
pmid:11809792
|
Shiotani A et al. |
Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. |
2002 |
Anat. Rec. |
pmid:12221720
|
Cremer I et al. |
Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. |
2002 |
Blood |
pmid:12393586
|
Giuliani N et al. |
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. |
2002 |
Blood |
pmid:12393684
|
Liao EY et al. |
Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. |
2002 |
J. Endocrinol. Invest. |
pmid:12398237
|
Haas M et al. |
Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. |
2002 |
Am. J. Kidney Dis. |
pmid:11877577
|
Goater JJ et al. |
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. |
2002 |
J. Orthop. Res. |
pmid:11918293
|
Roux S et al. |
RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. |
2002 |
Br. J. Haematol. |
pmid:11918537
|
Oshiro T et al. |
Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. |
2002 |
Anat. Rec. |
pmid:11920384
|
Hasegawa T et al. |
Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. |
2002 |
J. Periodont. Res. |
pmid:12472833
|
Yamashita T et al. |
Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. |
2002 |
Endocrinology |
pmid:12446599
|
Saidenberg Kermanac'h N et al. |
Osteoprotegerin and inflammation. |
2002 Apr-Jun |
Eur. Cytokine Netw. |
pmid:12101070
|
Jung K et al. |
Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. |
2002 Jul-Sep |
Int. J. Biol. Markers |
pmid:12408468
|
Stilgren LS et al. |
Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. |
2003 |
Calcif. Tissue Int. |
pmid:14667132
|
Okada T et al. |
Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. |
2003 |
Clin. Exp. Metastasis |
pmid:14669795
|
Gannagé-Yared MH et al. |
Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. |
2003 |
J. Endocrinol. Invest. |
pmid:14669830
|
Ashcroft AJ et al. |
Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. |
2003 |
Immunity |
pmid:14670302
|
Min JK et al. |
Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. |
2003 |
J. Biol. Chem. |
pmid:12893832
|
Chong B et al. |
Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. |
2003 |
J. Bone Miner. Res. |
pmid:14672344
|
Teitelbaum SL and Ross FP |
Genetic regulation of osteoclast development and function. |
2003 |
Nat. Rev. Genet. |
pmid:12897775
|
Nielsen KL et al. |
Biglycan deficiency interferes with ovariectomy-induced bone loss. |
2003 |
J. Bone Miner. Res. |
pmid:14672350
|
Si AI et al. |
Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. |
2003 |
J. Cell. Biochem. |
pmid:12898514
|
Nitta K et al. |
The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. |
2003 |
Am. J. Kidney Dis. |
pmid:12900812
|
Amizuka N et al. |
Defective bone remodelling in osteoprotegerin-deficient mice. |
2003 |
J Electron Microsc (Tokyo) |
pmid:14756238
|
Fizazi K et al. |
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. |
2003 |
Clin. Cancer Res. |
pmid:12855635
|
Kawana F and Sasaki T |
Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. |
2003 |
J Electron Microsc (Tokyo) |
pmid:14756239
|
Okuma K et al. |
Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. |
2003 |
J. Virol. |
pmid:12857926
|
Cheng X et al. |
The TNF receptor superfamily: role in immune inflammation and bone formation. |
2003 |
Immunol. Res. |
pmid:12857975
|
Shin MM et al. |
High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. |
2003 |
Exp. Mol. Med. |
pmid:12858015
|
Glossop JR et al. |
No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. |
2003 |
J. Rheumatol. |
pmid:12858434
|
Hampson G et al. |
Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. |
2003 |
Osteoporos Int |
pmid:12904840
|
Misra M et al. |
Serum osteoprotegerin in adolescent girls with anorexia nervosa. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12915674
|
Lonergan M et al. |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12915677
|
Abrahamsen B et al. |
Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. |
2003 |
Calcif. Tissue Int. |
pmid:12384814
|
Sezer O et al. |
RANK ligand and osteoprotegerin in myeloma bone disease. |
2003 |
Blood |
pmid:12424190
|
Yamada T et al. |
Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. |
2003 |
Blood |
pmid:12411305
|
Smith MD et al. |
Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. |
2003 |
Ann. Rheum. Dis. |
pmid:12634226
|
Sakurai A et al. |
Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. |
2003 |
Infect. Immun. |
pmid:14500523
|
Kim HH et al. |
RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. |
2003 |
FASEB J. |
pmid:14500543
|
Nakamura M et al. |
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. |
2003 |
Endocrinology |
pmid:14500574
|
Zhang Z et al. |
Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. |
2003 |
J. Immunol. |
pmid:14500659
|
Ueno Y et al. |
In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. |
2003 |
J. Cell. Biochem. |
pmid:14505343
|
Kaneyama K et al. |
Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. |
2003 |
Int J Oral Maxillofac Surg |
pmid:14505625
|
Grigorie D et al. |
Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. |
2003 |
Rom J Intern Med |
pmid:15526523
|
Ha H et al. |
Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. |
2003 |
J. Biol. Chem. |
pmid:12637570
|
Ritchlin CT et al. |
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. |
2003 |
J. Clin. Invest. |
pmid:12639988
|
Kido S et al. |
Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. |
2003 |
Bone |
pmid:12810169
|
Kudlacek S et al. |
Serum levels of osteoprotegerin increase with age in a healthy adult population. |
2003 |
Bone |
pmid:12810175
|
Mandelin J et al. |
Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. |
2003 |
J Bone Joint Surg Br |
pmid:14653607
|
Ikeda T et al. |
Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. |
2003 |
Pathol. Int. |
pmid:12828610
|
Malyszko J et al. |
Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. |
2003 |
Transplant. Proc. |
pmid:14529897
|
Crotti T et al. |
Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. |
2003 |
J. Periodont. Res. |
pmid:12828654
|
Ren W et al. |
Distinct gene expression of receptor activator of nuclear factor-kappaB and rank ligand in the inflammatory response to variant morphologies of UHMWPE particles. |
2003 |
Biomaterials |
pmid:14530078
|
Tazoe M et al. |
Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. |
2003 |
Arch. Oral Biol. |
pmid:12828991
|
Wiethe C et al. |
Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. |
2003 |
J. Immunol. |
pmid:14530334
|
Wiethe C et al. |
Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. |
2003 |
J. Immunol. |
pmid:12626542
|
Wagner EF and Matsuo K |
Signalling in osteoclasts and the role of Fos/AP1 proteins. |
2003 |
Ann. Rheum. Dis. |
pmid:14532157
|
Ueland T et al. |
Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12629078
|
Ueland T et al. |
Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. |
2003 |
Bone |
pmid:14555269
|
Schoppet M et al. |
Increased osteoprotegerin serum levels in men with coronary artery disease. |
2003 |
J. Clin. Endocrinol. Metab. |
pmid:12629080
|
Nagata N et al. |
Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. |
2003 |
Bone |
pmid:14555278
|
Han W et al. |
Construction of a new tumour necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. |
2003 |
Biotechnol. Appl. Biochem. |
pmid:12630898
|
Grimaud E et al. |
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. |
2003 |
Am. J. Pathol. |
pmid:14578201
|
Coen G et al. |
Serum leptin in dialysis renal osteodystrophy. |
2003 |
Am. J. Kidney Dis. |
pmid:14582047
|
Yorke R et al. |
Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. |
2003 |
Eur. J. Cancer |
pmid:12957466
|
Kaneyama K et al. |
Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. |
2003 |
Oral Surg Oral Med Oral Pathol Oral Radiol Endod |
pmid:12973279
|
Lee ZH and Kim HH |
Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. |
2003 |
Biochem. Biophys. Res. Commun. |
pmid:12745060
|
Boyle WJ et al. |
Osteoclast differentiation and activation. |
2003 |
Nature |
pmid:12748652
|
Terpos E et al. |
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. |
2003 |
Blood |
pmid:12689925
|
Zheng B et al. |
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. |
2003 |
Blood |
pmid:12689928
|
Moreno JL et al. |
IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. |
2003 |
Blood |
pmid:12689929
|
Dovio A et al. |
Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. |
2003 |
J. Endocrinol. |
pmid:12697042
|
Nakano M et al. |
Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. |
2003 |
Oral Dis |
pmid:12657033
|
Ra JS et al. |
Osteoprotegerin inhibits proliferation of myeloid progenitor cells. |
2003 |
J. Hematother. Stem Cell Res. |
pmid:12662434
|
Szalay F et al. |
High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. |
2003 |
J. Hepatol. |
pmid:12663228
|
Kato I et al. |
TRANCE together with IL-7 induces pre-B cells to proliferate. |
2003 |
Eur. J. Immunol. |
pmid:12548564
|
Sordillo EM and Pearse RN |
RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. |
2003 |
Cancer |
pmid:12548579
|
Oyajobi BO and Mundy GR |
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. |
2003 |
Cancer |
pmid:12548580
|
Croucher PI et al. |
Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. |
2003 |
Cancer |
pmid:12548581
|
Lipton A |
Bisphosphonates and metastatic breast carcinoma. |
2003 |
Cancer |
pmid:12548585
|
Demers LM |
Bone markers in the management of patients with skeletal metastases. |
2003 |
Cancer |
pmid:12548589
|
Body JJ et al. |
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. |
2003 |
Cancer |
pmid:12548591
|
Liu JZ et al. |
[The OPG/RANKL/RANK system and bone resorptive disease]. |
2003 |
Sheng Wu Gong Cheng Xue Bao |
pmid:15971575
|
Liu JZ et al. |
[Construction and biological activity study of human osteoprotegerin expressing adenoviral system]. |
2003 |
Sheng Wu Gong Cheng Xue Bao |
pmid:15969033
|
Elhasid R et al. |
Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. |
2003 |
Am. J. Hematol. |
pmid:12508266
|
Haynes DR et al. |
Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. |
2003 |
Rheumatology (Oxford) |
pmid:12509625
|